Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
JCR Pharmaceuticals CoTSE:4552 -0.38%42 Return-on-Tangible-Equity is 3.94% as of Mar. 2026, which is 59% below its 10-year median of 9.71. GuruFocus rates TSE:4552 with a GF Score™ of 42/100 and a GF Value™ of 円770.84 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 901 Drug Manufacturers companies, JCR Pharmaceuticals Co ranks worse than 59.38% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. JCR Pharmaceuticals Co's annualized net income for the quarter that ended in Mar. 2026 was 円1,736 Mil. JCR Pharmaceuticals Co's average shareholder tangible equity for the quarter that ended in Mar. 2026 was 円44,018 Mil. Therefore, JCR Pharmaceuticals Co's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 3.94%.
The historical rank and industry rank for JCR Pharmaceuticals Co's Return-on-Tangible-Equity or its related term are showing as below:
TSE:4552'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -9.19 Med: 9.71 Max: 34.93
Current: 4.92
During the past 13 years, JCR Pharmaceuticals Co's highest Return-on-Tangible-Equity was 34.93%. The lowest was -9.19%. And the median was 9.71%.
TSE:4552's Return-on-Tangible-Equity is ranked worse than 59.38% of 901
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs TSE:4552: 4.92
JCR Pharmaceuticals Co (TSE:4552) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
JCR Pharmaceuticals Co Return-on-Tangible-Equity Related Terms
JCR Pharmaceuticals Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for JCR Pharmaceuticals Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JCR Pharmaceuticals Co Return-on-Tangible-Equity Chart
TSE:4552 vs LLY, JNJ, ABBV: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - General subindustry, JCR Pharmaceuticals Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JCR Pharmaceuticals Co Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, JCR Pharmaceuticals Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where JCR Pharmaceuticals Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 3.94% mean?
JCR Pharmaceuticals Co (TSE:4552) has a Return-on-Tangible-Equity of 3.94% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on JCR Pharmaceuticals Co and its competitors. This is 59% below median its historical median of 9.71. According to the industry distribution chart, JCR Pharmaceuticals Co ranks #535 out of 901 companies in the Drug Manufacturers industry, placing it in the top 59.4%.
Is JCR Pharmaceuticals Co's Return-on-Tangible-Equity too high?
JCR Pharmaceuticals Co's current Return-on-Tangible-Equity of 3.94% is 59% below median its 10-year median of 9.71. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. JCR Pharmaceuticals Co's value of 3.94% is 50.1% below this industry median. Based on the distribution chart, JCR Pharmaceuticals Co ranks #535 out of 901 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, JCR Pharmaceuticals Co has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does JCR Pharmaceuticals Co's Return-on-Tangible-Equity compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, JCR Pharmaceuticals Co ranks #535 out of 901 companies for Return-on-Tangible-Equity. This places JCR Pharmaceuticals Co in the lower half of its industry. The industry median Return-on-Tangible-Equity is 7.90. JCR Pharmaceuticals Co's value of 3.94% is 50.1% below this benchmark. While the company's 10-year median is 9.71 vs. the industry median of 7.90, JCR Pharmaceuticals Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 901 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JCR Pharmaceuticals Co's current Return-on-Tangible-Equity of 3.94% is 50.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on JCR Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JCR Pharmaceuticals Co's current Return-on-Tangible-Equity is 3.94%, which is 59% below median its own 10-year median of 9.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JCR Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, JCR Pharmaceuticals Co (TSE:4552) is currently considered Possible Value Trap. The stock's GF Value™ is 円770.84, compared to a current price of 円522.00 — trading 32.3% below its estimated fair value. The current Return-on-Tangible-Equity is 3.94%, which is 59% below median its 10-year median of 9.71 and 50.1% below the Drug Manufacturers industry median of 7.90. JCR Pharmaceuticals Co's overall GF Score™ is 42/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For JCR Pharmaceuticals Co (TSE:4552), the current Return-on-Tangible-Equity is 3.94% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JCR Pharmaceuticals Co (TSE:4552) Overvalued in 2026?
Based on GuruFocus' analysis, JCR Pharmaceuticals Co stock appears to be undervalued.
The current stock price of 円522.00 is trading 32.3% below its estimated GF Value™ of 円770.84.
GuruFocus considers JCR Pharmaceuticals Co to be Possible Value Trap.
Key valuation signals for TSE:4552:
Return-on-Tangible-Equity: 3.94% (59% below median its 10-year median of 9.71)
GF Value™: 円770.84 vs. price of 円522.00 (32.3% below fair value)
Industry Position: 50.1% below the Drug Manufacturers median (#535 of 901)
No single metric tells the full story. See the TSE:4552 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JCR Pharmaceuticals Co Ltd is a major drug manufacturing company proactively engaged in the research of enzymes and proteins. The company maintains a focus toward developing value-added treatment options to address unmet medical needs. JCR utilizes international partnerships as a component of its growth strategy. The vast majority of JCR's revenue is generated from its pharmaceutical operations, followed by medical devices and laboratory equipment. A portion of the company's sales are derived from licensing agreements.
42GF Score
Get the complete analysis for TSE:4552
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4552 has been successfully added to your 
